Chronic inflammatory disorders such as psoriasis need therapy alternatives that retain effectiveness and tolerability over time. The study’s goal was to evaluate the long-term effectiveness and safety of brodalumab, a completely human anti-interleukin-17 receptor A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. In an open-label extension study, patients who completed a 12-week phase II dose-ranging clinical trial received brodalumab 210 mg every two weeks. The efficacy was determined using a static physician’s global assessment as well as the psoriasis area and severity index (PASI). The dermatological life quality index (DLQI) and safety were also examined. Brodalumab was given to 181 individuals for a median of 264 weeks. Brodalumab therapy resulted in immediate improvements in sPGA, PASI, and DLQI that lasted until week 264. When compared to PASI 75 to 90, reaching PASI 90 to 100 or PASI 100 at weeks 12, 240, and 264 was linked with a higher chance of DLQI 0 or 1. Over the course of five years, just one adverse event of suicidal thoughts was documented, no suicides occurred, and no new safety signals arose.

Throughout 5 years of therapy, brodalumab exhibited skin clearance and enhanced quality of life while maintaining an acceptable safety profile.